MARKET

CNAT

CNAT

Conatus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4657
+0.0307
+7.06%
Closed 16:00 02/21 EST
OPEN
0.4311
PREV CLOSE
0.4350
HIGH
0.4760
LOW
0.4270
VOLUME
914.08K
TURNOVER
--
52 WEEK HIGH
3.080
52 WEEK LOW
0.2500
MARKET CAP
15.45M
P/E (TTM)
-1.2049
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CNAT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CNAT stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

CNAT News

More
  • Histogen to Present at BIO CEO & Investor Conference
  • PR Newswire · 02/06 13:00
  • Gilead's Achilles' Heel - HIV Franchise In Serious Jeopardy
  • Seeking Alpha - Article · 02/04 15:55
  • Mid-Day Market Update: Dow Surges Over 150 Points; Avinger Shares Plunge
  • Benzinga · 01/29 17:11
  • Mid-Morning Market Update: Markets Mostly Flat; General Electric Profit Beats Expectations
  • Benzinga · 01/29 15:11

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CNAT

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
More

Webull offers kinds of Conatus Pharmaceuticals Inc stock information, including NASDAQ:CNAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNAT stock news, and many more online research tools to help you make informed decisions.